These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38423640)

  • 1. Efficacy and Safety of Anti-angiogenic Agents for Cancer Patients With Proteinuria or a History of Proteinuria: A Systematic Review.
    Kato T; Kurasawa S; Takezawa K; Fujiwara Y; Yasuda Y; Ando Y
    Anticancer Res; 2024 Mar; 44(3):889-894. PubMed ID: 38423640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
    Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
    Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
    Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
    Horsley L; Marti K; Jayson GC
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review.
    Kato T; Kawaguchi T; Funakoshi T; Fujiwara Y; Yasuda Y; Ando Y
    Cancer Diagn Progn; 2024; 4(4):390-395. PubMed ID: 38962544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Tao L; Zhang H; An G; Lan H; Xu Y; Ge Y; Yao J
    Front Oncol; 2021; 11():739263. PubMed ID: 34722290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.
    Kooijmans EC; Bökenkamp A; Tjahjadi NS; Tettero JM; van Dulmen-den Broeder E; van der Pal HJ; Veening MA
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008944. PubMed ID: 30855726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
    Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
    Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal surgery for kidney cancer: is preoperative proteinuria a predictor of functional and survival outcomes after surgery? A systematic review of the literature.
    Flammia RS; Tufano A; Proietti F; Gerolimetto C; DE Nunzio C; Franco G; Leonardo C
    Minerva Urol Nephrol; 2022 Jun; 74(3):255-264. PubMed ID: 34156198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
    Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
    Sasongko TH; Nagalla S; Ballas SK
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD009191. PubMed ID: 26041152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-immunosuppressive treatment for IgA nephropathy.
    Tunnicliffe DJ; Reid S; Craig JC; Samuels JA; Molony DA; Strippoli GF
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD003962. PubMed ID: 38299639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
    Chen S; Mo W; Jiang W; Zhou S; Gan H; Yu Q
    Front Immunol; 2023; 14():1218258. PubMed ID: 37614237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
    Albiges L; McGregor BA; Heng DYC; Procopio G; de Velasco G; Taguieva-Pioger N; Martín-Couce L; Tannir NM; Powles T
    Cancer Treat Rev; 2024 Jan; 122():102652. PubMed ID: 37980876
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.